Fig. 6: Localized in vivo gene-editing inhibits the postsurgical recurrence effectively.
From: In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy
(a) Schematic illustration of in vivo T-cell engineering treatment in a murine ectopic tumor recurrence model. The tumor growth (size) (b), survival curves (c), tumor weights (d) and body weights (e) are presented. For (b, c, e), 5 and 6 mice were analyzed (6 for PD1-CRISPR-Ele group, 5 for other groups). For (d), 4 and 6 mice were analyzed (6 for PD1-CRISPR-Ele group, 4 for other groups). Log-rank tests were performed to analyse the overall survival. Quantification of the proportion of CD3+ (f) and CD8+ (g) T-cells in the extracted tumor upon various treatments. h The percentage of the tumor-infiltrated CD8+GrzB+ T-cells in the tumor. i The percentage of Foxp3+ cells in CD4+ T-cells in tumor tissues collected from the treated mice. For (f−i), n = 4 mice in each group. The data are presented as mean ± s.e.m., analyzed using a one-way ANOVA with Tukey’s multiple comparison test. Source data are provided as a Source Data file.
